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ABSTRACT
Baseline demographic and phenotypic characteristics of patients aged ≥50 years in the 
Fabry Outcome Survey (Shire; data extracted June 2014) were compared with younger
adults to investigate potential factors influencing treatment decisions in later life. Age
groups were defined using age at treatment initiation or at FOS entry for untreated
patients: 18–49 (n = 1344; 49.5% male; 64.6% received agalsidase alfa enzyme
replacement therapy [ERT]); 50-64 (n = 537; 35.4% male; 74.3% treated); 65-74 (n =
137; 32.1% male; 68.6% treated); and ≥75 years (n = 26; 26.9% male; 50.0% treated). 
Successive age groups showed higher median age at first symptom and diagnosis.
Median alpha-galactosidase A activity, measured as percentage activity of the midpoint
of the normal range, was much greater in females than males of all groups except ≥75 
years (33.4% in females; 27.8% in males). Patients aged ≥75 years showed greater 
values than patients aged 18–49 years for median left ventricular mass indexed to height
(62.7 vs 42.4 g/m2.7), mean ventricular wall thickness (15.0 vs 10.0 mm) and prevalence
of hypertension (57.7% vs 21.8%), and lower median estimated glomerular filtration rate
(Modification of Diet in Renal Disease: 65.6 vs 98.5 mL/min/1.73 m2). Larger proportions
in the groups aged ≥50 exhibited cardiac and/or cerebrovascular manifestations 
compared with patients aged 18–49 years. The smaller proportion of patients receiving
ERT aged ≥75 years compared with the younger groups might reflect relatively milder 
disease burden or physician/patient reluctance to initiate/continue ERT at this age.
Further studies are needed to increase knowledge of Fabry disease and ERT in later life.
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Disease burden
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1. Introduction
Fabry disease results from a deficiency in lysosomal alpha-galactosidase A (α-Gal A) due 
to mutations in the GLA gene. This leads to the accumulation of globotriaosylceramide in
cells and a multi-system pathology.
Despite Fabry disease being X-linked, female heterozygotes can experience all of
the signs and symptoms of the disease, but generally later and with a milder, more
variable phenotype than in males [1-4]. Females may, however, on occasions have a
significant burden of disease, similar to that observed in males [5, 6]. The overall life
expectancy (calculated from birth) for patients with Fabry disease is 58 years for men
and 75 years for women [7].
Two broad phenotypes of Fabry disease are now recognised, the classical form
with childhood onset and multi-organ progression, and a later-onset phenotype with limited
organ involvement presenting in middle age. In classical Fabry disease, α-Gal A activity is 
greatly diminished, at <1% of normal in males, whereas patients with later-onset cardiac or
renal variants tend to have α-Gal A activity between 1% and 30% [8]. Diagnosis of the 
later-onset variant may be delayed due to lack of obvious external symptoms and signs
such as acroparesthesia and angiokeratoma. In all Fabry disease phenotypes, the natural
history of aging may be difficult to distinguish from Fabry-specific complications, which
themselves become more severe and prevalent with age.
Enzyme replacement therapy (ERT) in Fabry disease is expected to be most
successful when started early in the disease course [9-11]; its initiation has been
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recommended as soon as early clinical signs of kidney, heart or brain involvement
consistent with Fabry disease become apparent [12].
Family screening and symptom-based screening programmes have identified
people with Fabry disease in later-life stages and it is unclear whether the rationale for
starting treatment in this more advanced age group should be the same as for index cases
diagnosed at a younger age. Symptom-based therapy in these older patients may be more
beneficial, more cost effective and less burdensome to the health care provider than
starting ERT to prevent Fabry disease progression and clinical events. Few studies
focusing on elderly patients with Fabry disease have been performed; one analysis of six
patients indicated limited benefit in starting/continuing ERT in elderly patients in terms of
life expectancy and cost-effectiveness [13].
The objective of the present analysis was to describe the demographic and
phenotypic characteristics of patients who were ≥50 years of age in the Fabry Outcome 
Survey (FOS) and to compare them with younger adult patients in an attempt to identify
any factors that might influence the decision to treat, or not to treat, at later stages in life.
2. Methods
This was a retrospective analysis of data entered in FOS, a global, observational registry
sponsored by Shire for the collection of outcomes data on Fabry disease. A diagnosis of
Fabry disease is confirmed by reduced alpha-galactosidase A activity in plasma and
leukocytes in males, and by molecular analysis to confirm GLA mutations in females and
males. All patients with a confirmed diagnosis of Fabry disease who are receiving, or are
eligible for ERT with agalsidase alfa, can be registered in FOS. Patients who are
currently receiving ERT with a drug other than agalsidase alfa are not eligible for
inclusion in FOS. Data collection in FOS was initiated in 2001, and all patients aged ≥18 
years with data entered in FOS at the time of extraction (June 2014) were included.
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The institution review boards of each participating centre approved FOS and all
patients provided written informed consent prior to enrollment.
2.1 Populations analyzed
To analyze the presentation and clinical characteristics of elderly patients the population
in FOS was divided into the following age groups: patients 18–49 years, 50–64 years,
65–74 years and ≥75 years (elderly group). The groups were stratified by age at 
treatment initiation for treated patients and age at FOS entry for untreated patients.
Treated patients received agalsidase alfa 0.2 mg/kg body weight every other week.
2.2 Parameters evaluated
Patient demographics and the following baseline clinical characteristics were compared
between the age groups: cardiac parameters (obtained via echocardiography, according to
the American Society of Echocardiography recommendations) [14]: left ventricular mass
indexed to height (LVMI), left ventricular hypertrophy (LVH; >48 g/m2.7 in females and >50
g/m2.7 in males), mean ventricular wall thickness (MWT), aortic root diameter; renal
parameters: serum creatinine, estimated glomerular filtration rate (eGFR) using the
Modification of Diet in Renal Disease (MDRD) formula, Chronic Kidney Disease
Epidemiology Collaboration (CKD EPI) equation, urine protein. Chronic kidney disease
staging according to KDIGO guidelines [15] was performed for patients who had both
eGFR and albumin data available (Supplementary data Fig. S1).
Baseline cardiac, renal, cerebrovascular and auditory signs/symptoms were also
compared between the age groups of the overall population.
2.3 Statistical analysis
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Descriptive statistics were calculated for all continuous and categorical variables to
enable a thorough description of the demographic and clinical characteristics of patients
aged ≥50 years. 
3. Results
3.1 Enrollment and demographics
As of June 2014, a total of 2338 patients were enrolled in FOS (1279 females and 1059
males); 2044 of these were aged ≥18 years and are included in the current study. This 
study focuses on age rather than gender; however, data stratified by both age and
gender are provided for reference in Supplementary data Tables S1–S4.
The proportion of females increased with successive age group (Table 1). The
proportions of patients treated with ERT were 64.6% aged 18–49 years, 74.3% aged 50–
64, 68.6% aged 65–74 and 50.0% aged ≥75 years (Table 1). 
Median age at first symptom and diagnosis increased with each successive age
group, whereas the median delay in diagnosis was similar between the groups aged 50–
64 and 65–74 years (Table 1).
Median α-Gal A activity, measured as percentage activity of the midpoint of the 
normal range, was similar in females regardless of age, and generally much higher than in
males. In the elderly group, α-Gal A activity was at its highest in males (27.8% [13.6–
42.0%]) and thus closer to the level observed in females (33.4% [1.1–487.9%]; Table 1).
The largest proportion of Fabry disease diagnoses in each age group was made as
a result of family members being affected. Of the specialists who first suspected Fabry
disease, cardiologists diagnosed the largest proportions of patients in all groups aged ≥50 
years. Nephrologists diagnosed the largest proportion of patients aged 18–49 years (Table
1).
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The majority of patients were negative for heart pacemaker/transplant/defibrillator
use at any time (Table 1). Therapy with angiotensin-converting enzyme inhibitors and/or
angiotensin receptor blockers was more prevalent in patients who were aged ≥50 years 
than in younger adults (Table 1). Diabetes mellitus was more prevalent in patients aged
≥50 years than in younger adults (6.1% aged 50–64; 10.9% aged 65–74 and 3.8% aged 
≥75 years vs 1.4% aged 18–49 years), and hypertension prevalence decreased with 
decreasing age group (57.7% aged ≥75 years; 48.2% aged 65–74; 41.9% aged 50–64; 
21.8% aged 18–49; Table 1).
3.2 Phenotypic characteristics
3.2.1 Baseline cardiac parameters and events
A higher median baseline LVMI was demonstrated by Fabry patients presenting at a
more advanced age than in the youngest group (Fig. 1A). Similarly, median MWT was
progressively higher in the older groups (Fig. 1B).
Median aortic root diameter was similar for each of the age groups (see
Supplementary data Table S2 for aortic root diameter by gender).
The rate of cardiac events/manifestations experienced before treatment initiation or
FOS entry was greater in patients aged >50 years, where similar rates were experienced
by the groups aged 50–64 (81.0%) and 65–74 (80.3%), and the highest rate (88.5%) by
the elderly group. Fewer patients experienced any cardiac event/manifestation in the
youngest group (58.6%; Table 2). Left ventricular hypertrophy was the most prevalent
cardiac manifestation in each age group (Table 2).
3.2.2 Baseline renal parameters and events
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Median serum creatinine was similar in all age groups: 0.8 (range 0.4–14.6), 0.9 (0.3–
13.7), 1.0 (0.5–11.7) and 0.9 (0.6–10.3) mg/dL in patients aged 18–49, 50–64, 65–74
and ≥75 years, respectively. 
As expected, median eGFR calculated using the MDRD equation showed a
decrease with increasing age group and was lowest in the elderly group (Fig. 1C).
Similarly, median (range) eGFR calculated using the CKD-EPI formula also showed
a decrease with increasing age group, from 107.0 (0.0–172.6) mL/min/1.73 m2 in patients
aged 18–49 to 82.1 (3.0–117.7), 68.1 (3.9–101.4) and 60.8 (4.4–89.6) mL/min/1.73 m2 in
patients aged 50–64, 65–74 and ≥75 years, respectively. 
Median urine protein levels were 168.2 (range 0.0–4900.0), 148.2 (20.0–4640.0)
and 110.0 (47.6–2010.0) mg/24 h in the groups aged 50–64, 65–74 and ≥75 years, 
respectively, compared with 167.0 (0.0–9690.0) mg/24 h in the youngest group.
Any renal event/manifestation was experienced by a similar percentage of patients
in each of the age groups: 46.0% in patients aged 18–49 years, and 49.9%, 46.0% and
46.2% in patients aged 50–64, 65–74 and ≥75 years, respectively. 
Proteinuria/microalbuminuria was the most prevalent renal manifestation in all age groups
(Table 2).
Chronic kidney disease staging according to KDIGO guidelines [15] is summarized
in Supplementary data Figure S1.
3.2.3 Isolated cardiac and renal manifestations
The proportion of patients who reported isolated cardiac manifestations (defined as LVH
but no proteinuria) was highest in the elderly group (61.5%; n = 16) and decreased with
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decreasing age: 39.4% (n = 54), 38.5% (n = 207) and 16.9% (n = 227) in the groups
aged 65-74, 50–64 and 19–50 years, respectively.
Conversely, the proportion of patients with isolated renal manifestations (defined
as proteinuria but no LVH) was lowest in the elderly group (3.8%; n = 1) and increased
with decreasing age: 4.4% (n = 6), 7.1% (n = 38) and 18.8% (n = 253) in the groups aged
65–74, 50–64 and 18–49 years.
3.2.4 Cerebrovascular events
Any cerebrovascular event/manifestation was reported by a greater proportion of patients
in the groups aged 50–64 (24.2%), 65–74 (27.7%) and ≥75 years (19.2%) than in the 
youngest group (17.1%). Stroke was most prevalent in the groups older than 50 years
(Table 2).
3.2.5 Auditory events
A larger proportion of patients in the elderly group (57.7%) experienced auditory
events/manifestations than in the youngest group (45.7%). Hearing impairment was most
prevalent in the elderly group (Table 2).
4. Discussion
This study analyzed data collected in FOS to investigate whether a demographic and
phenotypic description could be made of patients aged ≥50 years that differentiate them 
from younger adult patients.
This analysis showed that a smaller proportion of older patients were treated with
ERT and that, after 50 years of age, the majority of ERT initiations were made in female
patients (Table 1). This indicates a possible reluctance of physicians and patients to
commence and/or continue ERT at older ages. The decision to either initiate or continue
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long-term ERT in patients with Fabry disease who are aged ≥50 years must take into 
account potential treatment benefits over costs to the healthcare system, and quality of
life. Factors for consideration regarding ERT initiation in elderly patients are outlined in
Figure 2 (Note to the Editor: Fig 2 to be inserted here [16]).
Since Fabry disease is a progressive disorder, disease severity and the degree of
organ involvement increase with age. Several recent reports have indicated that ERT in
patients with advanced disease has limited effectiveness [17-19], especially when initiated
after fibrosis has started to develop in the heart, kidney or central nervous system, which
may occur at a relatively early age in Fabry disease [20]. One study on patients who were
slightly older (40 ± 9 years) than in previously studied groups, and who were thus likely to
have more advanced disease, found that disease progression towards organ failure and
death was not halted by ERT over a period of approximately 6 years [18].
Initiating/continuing ERT in patients with Fabry disease who are ≥75 years may not be 
beneficial in terms of life expectancy or cost effectiveness [13]. The number of years since
symptom onset or diagnosis may be a better predictor of ERT refractory disease than
simply age.
The cardiac and renal signs and symptoms observed in the analysis population
aged ≥50 years were generally non-specific and could reflect the natural aging process. 
For example, compared with patients aged 18–49 years, older patients had a greater
prevalence of cardiac events/manifestations such as LVH and arrhythmia, decreases in
eGFR and increased prevalence of hearing impairment. Hearing loss, a common
occurrence during natural aging, was previously found to be independently predictive of
cardiac, renal and cerebrovascular complications in Fabry disease [21] and was the most
prevalent auditory event in the current study. Microalbuminuria is a known cardiovascular
risk factor in patients with hypertension [22], and microalbuminuria and proteinuria were
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the most prevalent renal manifestations in each age group in the current analysis. While
the prevalence of hypertension increased with successive age group, the prevalence of
microalbuminuria and proteinuria did not. Since the groups were stratified by age at
treatment initiation or FOS entry in untreated patients, this finding may reflect a lower
burden from microalbuminuria/proteinuria and a milder Fabry disease phenotype in the
older age groups than the younger group.
Whether patients have classical or later-onset Fabry disease may also require
consideration when making decisions regarding ERT initiation/continuation. We found that
age at symptom onset generally increased with successive age group. These data were
collected via patient recall, and thus must be interpreted carefully, but this increase may
reflect a predominance of de novo diagnosis of the later-onset phenotype in the groups
aged ≥50 years, rather than long-lived patients with early onset classical phenotypes. 
Furthermore, age at diagnosis tended to increase with successive age group and each
group also experienced delays in diagnosis, as found previously [3, 4]. The delay in
diagnosis doubled between the ages of 50 and 74 years, possibly because patients
presenting in these groups had limited disease with fewer symptoms characteristic of
Fabry disease. Angiokeratoma and tortuous ocular vessels, which may facilitate Fabry
disease diagnosis, were more prevalent in patients aged 18–49 years than in the older age
groups. Since the level of tortuosity is positively correlated with disease severity [23], this
could provide further evidence of limited disease in our population aged ≥50 years.  
Age at onset in patients with cardiac variant Fabry disease is reported to be in the
sixth to eighth decade [8]. In our study, compared with the younger adult group, the
prevalence of cardiac events/manifestations was greater in patients aged 65–74 and ≥75 
years, whereas that of renal events/manifestations generally remained similar or was
lower. The cardiac events in this group may be linked to the aging process or they might
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indicate a larger proportion of patients aged 65 years and above with the later-onset
cardiac variant of Fabry disease. If the main value of ERT is considered to be preventing
significant clinical events that might only occur years hence resulting from a lifetime of
storage deposition and secondary organ pathology, then the value of ERT in these
patients may be limited. However, it remains possible that, for those experiencing Fabry
symptoms not alleviated by conventional therapies, ERT might have a role in immediate
symptomatic benefit. An improvement in symptoms has been reported when ERT is
started in younger patients [24], but the efficacy of ERT in later-onset Fabry disease still
needs to be formally determined and a regimen for optimal supportive care and symptom
control carefully considered. Similarly, in classical patients receiving long-term ERT, there
is likely to come a point at which supportive and symptomatic care becomes more
important than limited ERT for long-term organ protection.
There were a number of limitations in our study. FOS is a rare disease registry, and
thus contains a relatively small number of patients, especially in the older age groups.
However, few exclusion criteria were applied; therefore the patient population was not
highly selected. Furthermore, a decline in number with aging would be expected in a
control population, although the low numbers did limit us to the use of descriptive statistics
only, making it difficult to draw conclusions from the data. The possibility of errors incurred
during data entry cannot be completely ruled out. While some values appeared to be high
(for example, upper range value for urine protein of 9690.0 mg/24 h in the youngest
group), these were considered to be within clinically feasible ranges; those that were
deemed implausible were excluded from analysis. Also, due to some missing data, the
trends observed will need to be followed up in order to be confirmed. Definitions of signs
and symptoms are not provided in FOS and thus are not standardized across participating
centres. Each physician determines their presence at patient visits according to
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predetermined criteria and records this information in the database primarily as "YES" or
"NO" variables. Further information on particular signs and symptoms is sparse, which
imposes some restrictions on the analyses that can subsequently be performed. It should
also be noted that standardized methods for measuring the clinical parameters are not
currently specified within FOS. A further possible limitation is that genetics data were not
available for inclusion; however, this paper represents a phenotypic analysis and reports
data, including residual α-Gal A activity data, from a large number of patients. Mutations 
associated with later-onset variants of Fabry disease could prove to be an interesting
focus for future studies.
5. Conclusions
This is the first report to date analyzing the phenotype of Fabry disease in patients aged
≥50 years. Some elderly patients who are experiencing Fabry-related complications and 
who are eligible for ERT are not receiving it. Further studies are required to delve deeper
into the reasons behind this, to show what types of supportive care are being provided
instead of or as well as ERT, and also to better define those who are suitable for ERT.
Although there may be limited benefits in initiating or continuing ERT in older patients
with more advanced Fabry disease, further investigations are warranted, particularly in
older patients with later-onset disease who may show a slower progression of Fabry
manifestations.
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Table 1
Summary of demographics and general clinical characteristics of the overall FOS population, stratified by age g
for α-Gal A activity). 
Parameter 18–49 years 50–64 years 65–74 years
Overall N = 1344 N = 537 N = 137
Males, n (%) 679 (50.5) 347 (64.6%) 93 (67.9)
Females, n (%) 665 (49.5%) 190 (35.4%) 44 (32.1)
Treated, n (%) 868 (64.6) 399 (74.3) 94 (68.6)
Males, n (%) 572 (65.9%) 161 (40.4%) 30 (31.9%)
Females, n (%) 296 (34.1%) 238 (59.6%) 64 (68.1%)
Age (years) at first symptom
N (missing) 857 (487) 315 (222) 77 (60)
Mean (SD) 16.6 (11.9) 32.2 (18.8) 47.8 (19.2)
Median (range) 12.0 (0.0–49.0) 34.0 (0.0–63.0) 54.0 (4.0–71.0)
Age (years) at diagnosis
N (missing) 1276 (68) 505 (32) 128 (9)
Mean (SD) 28.3 (11.5) 50.1 (11.2) 63.4 (10.3)
Median (range) 29.0 (0.0–50.0) 52.0 (4.0–64.0) 66.0 (11.0–74.0) 7
Delay (years) between symptom and diagnosis
N (missing) 847 (497) 311 (226) 75 (62)
Mean (SD) 10.9 (12.0) 16.3 (17.2) 14.7 (18.0)
Median (range) 8.0 (–33.0–41.0) 11.0 (–25.0–55.0) 10.0 (–35.0–62.0) 6
Age (years) at start of agalsidase alfa
N (missing) 868 (476) 399 (138) 94 (43)
Mean (SD) 35.2 (9.2) 56.6 (4.1) 69.1 (2.8)
Median (range) 35.6 (18.0–49.9) 56.3 (50.0–64.9) 68.6 (65.0–75.0) 7
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Time (years) to follow up
N (missing) 1344 (0) 537 (0) 137 (0)
Mean (SD) 3.8 (3.4) 2.9 (3.0) 2.5 (2.5)
Median (range) 2.9 (0.0–12.4) 1.9 (0.0–12.1) 1.7 (0.0–10.1)
Relatives in the cohort, n (%) 645 (48.0) 222 (41.3) 56 (40.9)
α-Gal A (% midpoint normal range) Male Female Male Female Male Female M
N (missing) 288 (377) 323 (356) 87 (103) 158 (189) 21 (23) 33 (60) 2
Mean (SD) 6.3 (7.6) 51.5 (36.6) 8.1 (9.6) 52.4 (35.1) 10.3 (13.8) 60.4 (60.7) 27.8
Median (range)
4.0 (0.0–
66.7)
44.0 (0.1–
212.0)
5.2 (0.0–
50.0)
47.6 (0.1–
181.8)
7.7 (0.2–
67.0)
44.0 (0.2–
251.5)
27.8
42
Specialist who first suspected disease, n (%) 414 182 45
Affected family member 470 (50.5) 139 (39.2) 38 (41.3)
Cardiologist 41 (4.4) 52 (14.6) 24 (26.1)
Dermatologist 39 (4.2) 14 (3.9) –
Gastroenterologist 1 (0.1) 1 (0.3) –
General practitioner 32 (3.4) 9 (2.5) 2 (2.2)
Geneticist 37 (4.0) 42 (11.8) 6 (6.5)
Internist 21 (2.3) 8 (2.3) 3 (3.3)
Nephrologist 120 (12.9) 30 (8.5) 7 (7.6)
Neurologist 37 (4.0) 18 (5.1) 1 (1.1)
Ophthalmologist 52 (5.6) 17 (4.8) 3 (3.3)
Other 36 (3.9) 19 (5.4) 6 (6.5)
Paediatrician 38 (4.1) 4 (1.1) 2 (2.2)
Rheumatologist 6 (0.6) 2 (0.6) –
ARB/ACE therapy any time, n (%) 408 (30.4) 238 (44.3) 72 (52.6)
Heart pacemaker/transplant/defibrillator, n (%) 10 (0.7) 21 (3.9) 4 (2.9)
Currently smoking, n (%) 103 (7.7) 28 (5.2) 2 (1.5)
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Smoking history, n (%) 171 (12.7) 78 (14.5) 18 (13.1)
Diabetes mellitus, n (%) 19 (1.4) 33 (6.1) 15 (10.9)
Hypertension, n (%) 293 (21.8) 225 (41.9) 66 (48.2)
Obesity (≥35 kg/m
2), n (%) 38 (2.8) 23 (4.3) 4 (2.9)
Tortuous vessels, n (%) 213 (15.8) 60 (11.2) 15 (10.9)
Angiokeratoma, n (%) 642 (47.8) 194 (36.1) 48 (35.0)
Raynaud Syndrome, n (%) 124 (9.2) 46 (8.6) 13 (9.5)
Malignancy, n (%) 17 (1.3) 24 (4.5) 9 (6.6)
Deceased recorded in database, n (%) 41 (3.1) 39 (7.3) 13 (9.5)
ACE = angiotensin-converting enzyme inhibitor; α-Gal A = alpha-galactosidase A; ARB = angiotensin receptor blocker.
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Table 2
Summary of cardiac, renal, cerebrovascular and auditory events/manifestations among the overall FOS popula t
age group.
Parameter 18–49 years(n = 1344)
50–64 years
(n = 537)
65–74 years
(n = 137)
≥75
(n
Any cardiac
event/manifestation, n (%)
787 (58.6) 435 (81.0) 110 (80.3) 23
Conduction abnormality 94 (7.0) 80 (14.9) 26 (19.0) 6
Fatigue 317 (23.6) 129 (24.0) 40 (29.2) 10
LVH 431 (32.1) 336 (62.6) 93 (67.9) 20
Heart failure 205 (15.3) 122 (22.7) 42 (30.7) 9
Arrhythmia 120 (8.9) 111 (20.7) 49 (35.8) 13
Cardiac surgery 15 (1.1) 29 (5.4) 10 (7.3) 4
Palpitations 220 (16.4) 111 (20.7) 27 (19.7) 6
Angina 44 (3.3) 54 (10.1) 18 (13.1) 1
Valve disease 125 (9.3) 75 (14.0) 24 (17.5) 7
Cardiac syncope 28 (2.1) 17 (3.2) 3 (2.2) 4
Dyspnea 131 (9.7) 108 (20.1) 39 (28.5) 7
Other (than listed) 129 (9.6) 115 (21.4) 33 (24.1) 6
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Any renal
event/manifestation, n (%)
618 (46.0) 268 (49.9) 63 (46.0) 12
Microalbuminuria 222 (16.5) 74 (13.8) 23 (16.8) 5
Peritoneal dialysis 8 (0.6) 2 (0.4) –
Proteinuria 457 (34.0) 167 (31.1) 45 (32.8) 5
Hematuria 82 (6.1) 29 (5.4) 7 (5.1) 1
Other (than listed) 79 (5.9) 56 (10.4) 18 (13.1) 4
Renal failure 116 (8.6) 71 (13.2) 18 (13.1) 2
Hemodialysis 42 (3.1) 19 (3.5) 2 (1.5)
Transplants 30 (2.2) 20 (3.7) 2 (1.5)
Unspecified dialysis 36 (2.7) 21 (3.9) 2 (1.5) 2
Any cerebrovascular
event/manifestation, n (%) 230 (17.1) 130 (24.2) 38 (27.7) 5
TIA 49 (3.6) 32 (6.0) 7 (5.1) 1
Other (than listed) 122 (9.1) 44 (8.2) 14 (10.2) 2
Stroke 96 (7.1) 73 (13.6) 26 (19.0) 4
PRIND 4 (0.3) 5 (0.9) –
Any auditory
event/manifestation, n (%)
614 (45.7) 256 (47.7) 64 (46.7) 15
Tinnitus 400 (29.8) 123 (22.9) 27 (19.7) 6
Vertigo 318 (23.7) 132 (24.6) 31 (22.6) 4
Sudden deafness 43 (3.2) 19 (3.5) 4 (2.9) 1
Hearing impairment 297 (22.1) 156 (29.1) 45 (32.8) 13
Other (than listed) 31 (2.3) 20 (3.7) 7 (5.1) 3
LVH = left ventricular hypertrophy; PRIND = prolonged reversible neurological deficits; TIA = transient ischemic attack.
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Fig. 1 Box plots showing A. Left ventricular mass indexed to height. B. Mean ventricular
wall thickness. C. Estimated glomerular filtration rate (eGFR) using the Modification of Diet
in Renal Disease formula (MDRD) for the patients in each age group.
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Fig. 2. Considerations in the decision to initiate ERT in patients with Fabry disease who
are older than 50 years.
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Highlights - Fabry in the older patient: clinical consequences and possibilities for
treatment (MGM-16-66)
￿ A smaller proportion aged ≥75 than <75 years received enzyme replacement therapy. 
￿ Not all elderly patients who are eligible are receiving enzyme replacement therapy. 
￿ The value of enzyme replacement therapy in the elderly needs further investigation. 
